economy
How investors killed AstraZeneca’s $400bn megadeal
Tie-up with US rival Bristol Myers would have marked return to big pharma mergers
TL;DR
- AstraZeneca's planned $400 billion merger with Bristol Myers Squibb was reportedly thwarted by significant investors.
- The proposed deal would have represented a major comeback for large mergers in the pharmaceutical sector.
- Key shareholders are believed to have been instrumental in preventing the tie-up.